Analysis of adherence to statin therapy among children with familial hypercholesterolemia: results of a 3-year prospective study
- Authors: Sadykova D.I1, Galimova L.F1,2, Slastnikova E.S1,2, Usova N.E2, Khaliullina C.D1
-
Affiliations:
- Kazan State Medical University
- Children's Republican Clinical Hospital, Kazan
- Issue: Vol 28, No 1 (2021)
- Pages: 81-85
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313062
- DOI: https://doi.org/10.18565/pharmateca.2021.1.81-85
- ID: 313062
Cite item
Open Access
Access granted
Abstract
Background. Familial hypercholesterolemia (FH) is a frequent genetic disease associated with the premature development of atherosclerosis. Patients with FH who do not receive treatment are at high risk of atherosclerotic diseases after 20 years. According to international and Russian recommendations, statin treatment should be considered in children with heterozygous form of the disease from the age of 8-10 years. Objective. Evaluation of the adherence to statin therapy among children with FH and analysis of contributing factors. Methods. For the period 2017-2020, 56 children with heterozygous FH were included in the study. The mean age of children was 13.92±3.1 years, the mean total cholesterol level - 7.8±2.1 mmol/L, low-density lipoproteins (LDL) - 6.0±1.1 mmol/L. All patients were prescribed atorvastatin at a starting dose of 10 mg. At follow-up visit after 1 month, only 4 (7%) children started statin therapy. Results. The children of this group achieved LDL targets <3.5 mmol/l. At the next follow-up visit, after 3 months, another child began taking atorvastatin. By the end of the reported follow-up period (12 months), the proportion of patients taking statins had not increased, and amounted to 5 (9%) children. Against the background of treatment, none of the children had complaints and side effects. Based on the questionnaire, an analysis of the reasons for patients’ refusal of treatment was carried out. Reasons for lack of adherence to treatment were divided into three categories: patient-related, physician-related, and health system-related. Conclusion. Modern lipid-lowering therapy has tremendous potential to improve prognosis in patients with FH. However, there is low adherence to statin treatment in pediatric practice. The main ways to solve the problem include psychological counselling, creation of a trust union between the doctor and the patient, as well as increasing the awareness of both patients and medical professionals.
Full Text
About the authors
D. I Sadykova
Kazan State Medical University
Email: sadykovadi@mail.ru
Dr. Sci. (Med.), Head of the Department of Hospital Pediatrics
L. F Galimova
Kazan State Medical University; Children's Republican Clinical Hospital, Kazan
E. S Slastnikova
Kazan State Medical University; Children's Republican Clinical Hospital, Kazan
N. E Usova
Children's Republican Clinical Hospital, Kazan
Ch. D Khaliullina
Kazan State Medical University
References
- Duerden M., O'Flynn N., Qureshi N. Cardiovascular risk assessment and lipid modification: NICE guideline. Br J. Gen Pract. 2015;65(636):378-80. doi: 10.3399/bjgp15X685933.
- Mendis S., Puska P., Norrving B. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization, 2011.
- Mozaffarian D., Benjamin E.J., Go A.S., et al. Heart disease and stroke statistics - 2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38-60. Doi: 10.1161/ CIR.0000000000000350.
- Ebrahim S., Taylor F.C., Brindle P. Statins for the primary prevention of cardiovascular disease. BMJ. 2014;348:g280. doi: 10.1136/bmj.g280.
- Gu Q., Paulose-Ram R., Burt V.L., et al. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS Data Brief. 2014;(177):1-8.
- Fulcher J., O'Connell R., Voysey M., et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397-405. doi: 10.1016/S0140-6736(14)61368-4.
- Mihaylova B., Emberson J., Blackwell L., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5.
- Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376:1670-81. Doi: 10.1016/ S0140-6736(10)61350-5.
- Di Angelantonio E., Sarwar N., Perry P., et al. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;11;302(18):1993-2000. doi: 10.1001/jama.2009.1619.
- Клинические рекомендации. Семейная гипер-холестеринемия. 2018 г. Электронный источник. [Clinical guidelines. Familial hypercholesterolemia. 2018 Electronic source. (In Russ.)]. URL: https:// noatero.ru/sites/default/files/proekt_klinicheskie_ rekomendacii_sghs_mz_rf_18.01.pdf.
- Ference B.A., Ginsberg H.N., Graham I., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72. doi: 10.1093/eurheartj/ ehx144.
- Grundy S.M., Arai H., Barter P, et al. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia - full report. J Clin Lipidol. 2014;8:29 60. doi: 10.1016/j.jacl.2013.12.005
- Luirink I.K., Wiegman A., Kusters D.M., et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N. Engl J. Med. 2019;381(16):1547-56. Doi: 10.1056/ nejmoa1816454.
- Wiegman A., Gidding S.S., Watts G.F., et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-37. doi: 10.1093/eurheartj/ehv157.
- Mach F., Baigent C., Catapano A.I., et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;00:1-78. doi: 10.1093/eurheartj/ ehz455.
- Neil H.A., Hammond T., Huxley R., et al. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ. 2000;15;321(7254):148. Doi: 10.1136/ bmj.321.7254.148.
- Ramaswami U., Futema M., Bogsrud M.P., et al. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis. 2020; 1(292)178-87. Doi: https://doi.org/10.1016/j. atherosclerosis.2019.11.012.
Supplementary files
